Jun 2026 (Q2 FY26) — Aug 6, 2026
Progyny Q2 FY26 — Strong Sales Momentum & Cash Flow Despite Q3 Seasonality
Read the full callProgyny (PGNY) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Progyny earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 351 | +5.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 11.4 | +4.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 28.1 | +63.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$27.46 −1.36% · −$0.38
Performance +35.7% 1Y
1Y: $20.23 on 14 Oct 2025 → $27.46. High $32.36 (14 Jul 2026), low $16.3 (10 Apr 2026).
- Previous close
- $27.84
- 52-week range
- $16.3 – $32.36
- One year
- +35.14%
Overview
- Symbol
- PGNY
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Progyny earnings calls (PGNY)
Financials
What the filings say
Net profit, year on year: +64% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 287 | 298 | 324 | 333 | 313 | 318 | 329 | 351 |
| Operating profit | 12 | 16 | 24 | 24 | 22 | 15 | 35 | 40 |
| Operating margin | 4.3% | 5.3% | 7.5% | 7.3% | 6.9% | 4.8% | 10.8% | 11.4% |
| Other income | 6 | — | — | — | — | — | — | — |
| Profit before tax | 18 | 18 | 27 | 27 | 24 | 18 | 37 | 41 |
| Tax rate | 42.0% | 40.4% | 43.3% | 36.8% | 42.1% | 30.1% | 34.3% | 31.8% |
| Net profit | 10 | 11 | 15 | 17 | 14 | 12 | 24 | 28 |
| EPS ($ per share) | 0.12 | 0.12 | 0.18 | 0.20 | 0.16 | 0.15 | 0.30 | 0.36 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -105 | -113 | -68 | -2 | 28 | 90 | 144 | 203 |
| Total liabilities | 30 | 36 | 87 | 106 | 166 | 203 | 185 | 226 |
| Fixed assets | 1 | 3 | 3 | 5 | 8 | 10 | 12 | 30 |
| Investments | — | — | 39 | — | — | — | — | — |
| Total assets | 41 | 150 | 254 | 358 | 543 | 757 | 607 | 742 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2 | -2 | 36 | 26 | 80 | 189 | 179 | 210 |
| Cash from investing | 2 | -3 | -40 | 9 | -44 | -201 | 196 | -159 |
| Cash from financing | -9 | 85 | -6 | -14 | -8 | -11 | -310 | -99 |
| Net cash flow | — | — | -10 | 21 | 29 | -23 | 65 | -48 |
| Capital expenditure | -1 | -3 | -1 | -2 | -3 | -4 | -5 | -18 |
| Free cash flow | 2 | -4 | 35 | 24 | 77 | 185 | 174 | 192 |
Insider filings
86 filings between Nov 10, 2025 and Sep 23, 2026.
Open market
decisions to buy or sellPurchases
$1.93M
1 purchase by 1 insider
Sales
$2.25M
23 sales by 6 insiders
83% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 15
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 40
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 other filings, 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Anevski Peter | $1.93M | — | Nov 13, 2025 |
| Livingston Mark S. | — | $842.9K | Jun 4, 2026 |
| GORDON KEVIN K | — | $449.3K | Sep 10, 2026 |
| Swartz Allison | — | $414.9K | Sep 23, 2026 |
| Cummings Melissa B | — | $310.4K | Jul 14, 2026 |
| Scott Cheryl | — | $196.3K | Jun 1, 2026 |
| Clapp Geoffrey | — | $39.1K | Jun 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 23, 2026 | Swartz Allison EVP, GC | Sale 10b5-1 plan | 3,903 | $101.9K |
| Sep 17, 2026 | Clapp Geoffrey Chief Product Officer | Tax withheld | 819 | $22.4K |
| Sep 10, 2026 | GORDON KEVIN K Director | Tax withheld | 10,500 | $286.0K |
| Sep 10, 2026 | GORDON KEVIN K Director | Option exercise | 22,000 | $286.0K |
| Sep 10, 2026 | GORDON KEVIN K Director | Sale | 11,500 | $311.9K |
| Sep 4, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Tax withheld | 479 | $12.7K |
| Sep 4, 2026 | Swartz Allison EVP, GC | Tax withheld | 479 | $12.7K |
| Sep 3, 2026 | Anevski Peter CHIEF EXECUTIVE OFFICER | Tax withheld | 5,361 | $140.9K |
| Sep 3, 2026 | Swartz Allison EVP, GC | Tax withheld | 828 | $21.8K |
| Sep 3, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Tax withheld | 1,532 | $40.3K |
| Sep 2, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Tax withheld | 224 | $5.7K |
| Aug 28, 2026 | Swartz Allison EVP, GC | Tax withheld | 1,352 | $35.0K |
| Jul 14, 2026 | Cummings Melissa B Chief Operating Officer | Tax withheld 10b5-1 plan | 1,193 | $38.2K |
| Jul 14, 2026 | Cummings Melissa B Chief Operating Officer | Sale 10b5-1 plan | 2,244 | $70.9K |
| Jun 17, 2026 | Clapp Geoffrey Chief Product Officer | Tax withheld | 819 | $21.8K |
| Jun 4, 2026 | Swartz Allison EVP, GC | Tax withheld 10b5-1 plan | 339 | $8.5K |
| Jun 4, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 599 | $15.3K |
| Jun 4, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 1,918 | $48.9K |
| Jun 4, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Tax withheld 10b5-1 plan | 339 | $8.5K |
| Jun 4, 2026 | Swartz Allison EVP, GC | Sale 10b5-1 plan | 599 | $15.0K |
| Jun 3, 2026 | Anevski Peter CHIEF EXECUTIVE OFFICER | Tax withheld | 5,361 | $134.7K |
| Jun 3, 2026 | Swartz Allison EVP, GC | Sale 10b5-1 plan | 1,199 | $30.0K |
| Jun 3, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Tax withheld 10b5-1 plan | 1,082 | $27.2K |
| Jun 3, 2026 | Swartz Allison EVP, GC | Tax withheld 10b5-1 plan | 676 | $17.0K |
| Jun 2, 2026 | Clapp Geoffrey Chief Product Officer | Tax withheld | 11,379 | $290.6K |
| Jun 2, 2026 | Clapp Geoffrey Chief Product Officer | Option exercise | 12,909 | $269.9K |
| Jun 2, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 279 | $7.3K |
| Jun 2, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Tax withheld 10b5-1 plan | 158 | $4.1K |
| Jun 2, 2026 | Clapp Geoffrey Chief Product Officer | Sale | 1,530 | $39.1K |
| Jun 1, 2026 | Scott Cheryl Director | Tax withheld | 7,228 | $190.7K |
| Jun 1, 2026 | Scott Cheryl Director | Option exercise | 14,667 | $190.7K |
| Jun 1, 2026 | Scott Cheryl Director | Sale | 7,439 | $196.3K |
| May 28, 2026 | Swartz Allison EVP, GC | Sale 10b5-1 plan | 2,398 | $61.1K |
| May 28, 2026 | Swartz Allison EVP, GC | Tax withheld 10b5-1 plan | 1,352 | $34.4K |
| May 27, 2026 | GORDON KEVIN K Director | Other | 2,526 | $0 |
| May 27, 2026 | GORDON KEVIN K Director | Other | 2,526 | $0 |
| May 27, 2026 | GORDON KEVIN K Director | Sale | 5,500 | $137.4K |
| May 21, 2026 | GORDON KEVIN K Director | Award | 6,792 | $0 |
| May 21, 2026 | Park Jeffrey G Director | Award | 7,924 | $0 |
| May 21, 2026 | Payson Norman Director | Award | 5,660 | $0 |
| May 21, 2026 | Scott Cheryl Director | Award | 5,660 | $0 |
| May 21, 2026 | MORRIS DEBRA L Director | Award | 5,660 | $0 |
| May 21, 2026 | HOLSTEIN ROGER C Director | Award | 6,792 | $0 |
| May 21, 2026 | Bierbower Elizabeth D Director | Award | 5,660 | $0 |
| May 21, 2026 | Dean Lloyd H Director | Award | 6,792 | $0 |
| May 20, 2026 | Livingston Mark S. CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 8,275 | $211.0K |
| May 19, 2026 | Cummings Melissa B Chief Operating Officer | Sale 10b5-1 plan | 9,578 | $239.4K |
| Apr 14, 2026 | Cummings Melissa B Chief Operating Officer | Tax withheld | 4,172 | $70.8K |
| Mar 17, 2026 | Clapp Geoffrey Chief Product Officer | Tax withheld | 3,275 | $57.1K |
| Mar 4, 2026 | Swartz Allison EVP, GC | Sale 10b5-1 plan | 599 | $10.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Progyny, Inc.
Free account. Everything above stays public.
Write why you follow Progyny, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading